Review





Similar Products

selection operator lasso binary logistic regression model  (Genovis Inc)
99
Genovis Inc selection operator lasso binary logistic regression model
Selection Operator Lasso Binary Logistic Regression Model, supplied by Genovis Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/selection operator lasso binary logistic regression model/product/Genovis Inc
Average 99 stars, based on 1 article reviews
selection operator lasso binary logistic regression model - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
selection operator lasso logistic regression model  (Genovis Inc)
99
Genovis Inc selection operator lasso logistic regression model
Prediction of CDPS and the correlation <t>between</t> <t>proteomics</t> and clinical characteristics. A . Heatmap of the correlation among expression of co-expression protein modules, expression of CDPS key proteins and clinical characteristics (IFX, response to infliximab; UST, response to ustekinumab; PS, psoriasis; NEUT, neutrophils; CRP, C-reactive protein; WBC, white blood cell; ESR, erythrocyte sedimentation rate; ALB, albumin; SES-CD, simple endoscopic score for Crohn's Disease); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. B . Heatmap of correlation between immune cell infiltration and expression of co-expression modules and CDPS key proteins; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. C . Box plot of expression of co-expression modules in response (R) and non-response (NR) group (UST, ustekinumab; IFX, infliximab); UST (NR) n = 6, UST (R) n = 11; IFX (NR) n = 13, IFX (R) n = 6, Wilcoxon rank-sum test, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. D . Box plot of level of immune cells infiltration in response (R) and non-response (NR) group (UST: ustekinumab; IFX, infliximab); UST (NR) n = 6, UST (R) n = 11; IFX (NR) n = 13, IFX (R) n = 6, Wilcoxon rank-sum test, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. E . Heatmap of correlation between immune cells infiltration and each of the following: response to ustekinumab, response to infliximab, and the occurrence of psoriasis (IFX, response to infliximab; UST, response to ustekinumab; PS, psoriasis); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. F . ROC curves of prediction models (validation group) for the likelihood of achieving an endoscopic response by intestinal mucosa proteomics; activated CD8 T cell AUC: 0.675 (95% CI: 0.333–1.000), turquoise AUC: 0.750 (95% CI: 0.500–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000). G . ROC curves of prediction models (validation group) for the likelihood of achieving an endoscopic response by body fluids proteomics; HGFAC (plasma) AUC: 0.780 (95% CI: 0.333–1.000), HGFAC (urine) AUC: 0.780 (95% CI: 0.333–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000). H . ROC curves of prediction models (validation group) for likelihood of the development of CDPS constructed using selected features by <t>lasso</t> regression; turquoise AUC: 0.960 (95% CI: 0.750–1.000), KRT7 AUC: 0.622 (95% CI: 0.333–1.000), HGFAC (plasma) AUC: 0.750 (95% CI: 0.500–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000).
Selection Operator Lasso Logistic Regression Model, supplied by Genovis Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/selection operator lasso logistic regression model/product/Genovis Inc
Average 99 stars, based on 1 article reviews
selection operator lasso logistic regression model - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
absolute shrinkage selection operator llm large language model lr logistic regression mae mean absolute error mdi mean decrease  (Genovis Inc)
99
Genovis Inc absolute shrinkage selection operator llm large language model lr logistic regression mae mean absolute error mdi mean decrease
Prediction of CDPS and the correlation <t>between</t> <t>proteomics</t> and clinical characteristics. A . Heatmap of the correlation among expression of co-expression protein modules, expression of CDPS key proteins and clinical characteristics (IFX, response to infliximab; UST, response to ustekinumab; PS, psoriasis; NEUT, neutrophils; CRP, C-reactive protein; WBC, white blood cell; ESR, erythrocyte sedimentation rate; ALB, albumin; SES-CD, simple endoscopic score for Crohn's Disease); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. B . Heatmap of correlation between immune cell infiltration and expression of co-expression modules and CDPS key proteins; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. C . Box plot of expression of co-expression modules in response (R) and non-response (NR) group (UST, ustekinumab; IFX, infliximab); UST (NR) n = 6, UST (R) n = 11; IFX (NR) n = 13, IFX (R) n = 6, Wilcoxon rank-sum test, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. D . Box plot of level of immune cells infiltration in response (R) and non-response (NR) group (UST: ustekinumab; IFX, infliximab); UST (NR) n = 6, UST (R) n = 11; IFX (NR) n = 13, IFX (R) n = 6, Wilcoxon rank-sum test, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. E . Heatmap of correlation between immune cells infiltration and each of the following: response to ustekinumab, response to infliximab, and the occurrence of psoriasis (IFX, response to infliximab; UST, response to ustekinumab; PS, psoriasis); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. F . ROC curves of prediction models (validation group) for the likelihood of achieving an endoscopic response by intestinal mucosa proteomics; activated CD8 T cell AUC: 0.675 (95% CI: 0.333–1.000), turquoise AUC: 0.750 (95% CI: 0.500–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000). G . ROC curves of prediction models (validation group) for the likelihood of achieving an endoscopic response by body fluids proteomics; HGFAC (plasma) AUC: 0.780 (95% CI: 0.333–1.000), HGFAC (urine) AUC: 0.780 (95% CI: 0.333–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000). H . ROC curves of prediction models (validation group) for likelihood of the development of CDPS constructed using selected features by <t>lasso</t> regression; turquoise AUC: 0.960 (95% CI: 0.750–1.000), KRT7 AUC: 0.622 (95% CI: 0.333–1.000), HGFAC (plasma) AUC: 0.750 (95% CI: 0.500–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000).
Absolute Shrinkage Selection Operator Llm Large Language Model Lr Logistic Regression Mae Mean Absolute Error Mdi Mean Decrease, supplied by Genovis Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/absolute shrinkage selection operator llm large language model lr logistic regression mae mean absolute error mdi mean decrease/product/Genovis Inc
Average 99 stars, based on 1 article reviews
absolute shrinkage selection operator llm large language model lr logistic regression mae mean absolute error mdi mean decrease - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
regression logistic model lasso  (Genovis Inc)
99
Genovis Inc regression logistic model lasso
Prediction of CDPS and the correlation <t>between</t> <t>proteomics</t> and clinical characteristics. A . Heatmap of the correlation among expression of co-expression protein modules, expression of CDPS key proteins and clinical characteristics (IFX, response to infliximab; UST, response to ustekinumab; PS, psoriasis; NEUT, neutrophils; CRP, C-reactive protein; WBC, white blood cell; ESR, erythrocyte sedimentation rate; ALB, albumin; SES-CD, simple endoscopic score for Crohn's Disease); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. B . Heatmap of correlation between immune cell infiltration and expression of co-expression modules and CDPS key proteins; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. C . Box plot of expression of co-expression modules in response (R) and non-response (NR) group (UST, ustekinumab; IFX, infliximab); UST (NR) n = 6, UST (R) n = 11; IFX (NR) n = 13, IFX (R) n = 6, Wilcoxon rank-sum test, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. D . Box plot of level of immune cells infiltration in response (R) and non-response (NR) group (UST: ustekinumab; IFX, infliximab); UST (NR) n = 6, UST (R) n = 11; IFX (NR) n = 13, IFX (R) n = 6, Wilcoxon rank-sum test, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. E . Heatmap of correlation between immune cells infiltration and each of the following: response to ustekinumab, response to infliximab, and the occurrence of psoriasis (IFX, response to infliximab; UST, response to ustekinumab; PS, psoriasis); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. F . ROC curves of prediction models (validation group) for the likelihood of achieving an endoscopic response by intestinal mucosa proteomics; activated CD8 T cell AUC: 0.675 (95% CI: 0.333–1.000), turquoise AUC: 0.750 (95% CI: 0.500–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000). G . ROC curves of prediction models (validation group) for the likelihood of achieving an endoscopic response by body fluids proteomics; HGFAC (plasma) AUC: 0.780 (95% CI: 0.333–1.000), HGFAC (urine) AUC: 0.780 (95% CI: 0.333–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000). H . ROC curves of prediction models (validation group) for likelihood of the development of CDPS constructed using selected features by <t>lasso</t> regression; turquoise AUC: 0.960 (95% CI: 0.750–1.000), KRT7 AUC: 0.622 (95% CI: 0.333–1.000), HGFAC (plasma) AUC: 0.750 (95% CI: 0.500–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000).
Regression Logistic Model Lasso, supplied by Genovis Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/regression logistic model lasso/product/Genovis Inc
Average 99 stars, based on 1 article reviews
regression logistic model lasso - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
regression logistic 442 model lasso  (Genovis Inc)
99
Genovis Inc regression logistic 442 model lasso
Prediction of CDPS and the correlation <t>between</t> <t>proteomics</t> and clinical characteristics. A . Heatmap of the correlation among expression of co-expression protein modules, expression of CDPS key proteins and clinical characteristics (IFX, response to infliximab; UST, response to ustekinumab; PS, psoriasis; NEUT, neutrophils; CRP, C-reactive protein; WBC, white blood cell; ESR, erythrocyte sedimentation rate; ALB, albumin; SES-CD, simple endoscopic score for Crohn's Disease); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. B . Heatmap of correlation between immune cell infiltration and expression of co-expression modules and CDPS key proteins; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. C . Box plot of expression of co-expression modules in response (R) and non-response (NR) group (UST, ustekinumab; IFX, infliximab); UST (NR) n = 6, UST (R) n = 11; IFX (NR) n = 13, IFX (R) n = 6, Wilcoxon rank-sum test, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. D . Box plot of level of immune cells infiltration in response (R) and non-response (NR) group (UST: ustekinumab; IFX, infliximab); UST (NR) n = 6, UST (R) n = 11; IFX (NR) n = 13, IFX (R) n = 6, Wilcoxon rank-sum test, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. E . Heatmap of correlation between immune cells infiltration and each of the following: response to ustekinumab, response to infliximab, and the occurrence of psoriasis (IFX, response to infliximab; UST, response to ustekinumab; PS, psoriasis); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. F . ROC curves of prediction models (validation group) for the likelihood of achieving an endoscopic response by intestinal mucosa proteomics; activated CD8 T cell AUC: 0.675 (95% CI: 0.333–1.000), turquoise AUC: 0.750 (95% CI: 0.500–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000). G . ROC curves of prediction models (validation group) for the likelihood of achieving an endoscopic response by body fluids proteomics; HGFAC (plasma) AUC: 0.780 (95% CI: 0.333–1.000), HGFAC (urine) AUC: 0.780 (95% CI: 0.333–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000). H . ROC curves of prediction models (validation group) for likelihood of the development of CDPS constructed using selected features by <t>lasso</t> regression; turquoise AUC: 0.960 (95% CI: 0.750–1.000), KRT7 AUC: 0.622 (95% CI: 0.333–1.000), HGFAC (plasma) AUC: 0.750 (95% CI: 0.500–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000).
Regression Logistic 442 Model Lasso, supplied by Genovis Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/regression logistic 442 model lasso/product/Genovis Inc
Average 99 stars, based on 1 article reviews
regression logistic 442 model lasso - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
regression logistic 242 model lasso  (Genovis Inc)
99
Genovis Inc regression logistic 242 model lasso
Prediction of CDPS and the correlation <t>between</t> <t>proteomics</t> and clinical characteristics. A . Heatmap of the correlation among expression of co-expression protein modules, expression of CDPS key proteins and clinical characteristics (IFX, response to infliximab; UST, response to ustekinumab; PS, psoriasis; NEUT, neutrophils; CRP, C-reactive protein; WBC, white blood cell; ESR, erythrocyte sedimentation rate; ALB, albumin; SES-CD, simple endoscopic score for Crohn's Disease); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. B . Heatmap of correlation between immune cell infiltration and expression of co-expression modules and CDPS key proteins; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. C . Box plot of expression of co-expression modules in response (R) and non-response (NR) group (UST, ustekinumab; IFX, infliximab); UST (NR) n = 6, UST (R) n = 11; IFX (NR) n = 13, IFX (R) n = 6, Wilcoxon rank-sum test, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. D . Box plot of level of immune cells infiltration in response (R) and non-response (NR) group (UST: ustekinumab; IFX, infliximab); UST (NR) n = 6, UST (R) n = 11; IFX (NR) n = 13, IFX (R) n = 6, Wilcoxon rank-sum test, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. E . Heatmap of correlation between immune cells infiltration and each of the following: response to ustekinumab, response to infliximab, and the occurrence of psoriasis (IFX, response to infliximab; UST, response to ustekinumab; PS, psoriasis); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. F . ROC curves of prediction models (validation group) for the likelihood of achieving an endoscopic response by intestinal mucosa proteomics; activated CD8 T cell AUC: 0.675 (95% CI: 0.333–1.000), turquoise AUC: 0.750 (95% CI: 0.500–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000). G . ROC curves of prediction models (validation group) for the likelihood of achieving an endoscopic response by body fluids proteomics; HGFAC (plasma) AUC: 0.780 (95% CI: 0.333–1.000), HGFAC (urine) AUC: 0.780 (95% CI: 0.333–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000). H . ROC curves of prediction models (validation group) for likelihood of the development of CDPS constructed using selected features by <t>lasso</t> regression; turquoise AUC: 0.960 (95% CI: 0.750–1.000), KRT7 AUC: 0.622 (95% CI: 0.333–1.000), HGFAC (plasma) AUC: 0.750 (95% CI: 0.500–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000).
Regression Logistic 242 Model Lasso, supplied by Genovis Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/regression logistic 242 model lasso/product/Genovis Inc
Average 99 stars, based on 1 article reviews
regression logistic 242 model lasso - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

Image Search Results


Prediction of CDPS and the correlation between proteomics and clinical characteristics. A . Heatmap of the correlation among expression of co-expression protein modules, expression of CDPS key proteins and clinical characteristics (IFX, response to infliximab; UST, response to ustekinumab; PS, psoriasis; NEUT, neutrophils; CRP, C-reactive protein; WBC, white blood cell; ESR, erythrocyte sedimentation rate; ALB, albumin; SES-CD, simple endoscopic score for Crohn's Disease); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. B . Heatmap of correlation between immune cell infiltration and expression of co-expression modules and CDPS key proteins; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. C . Box plot of expression of co-expression modules in response (R) and non-response (NR) group (UST, ustekinumab; IFX, infliximab); UST (NR) n = 6, UST (R) n = 11; IFX (NR) n = 13, IFX (R) n = 6, Wilcoxon rank-sum test, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. D . Box plot of level of immune cells infiltration in response (R) and non-response (NR) group (UST: ustekinumab; IFX, infliximab); UST (NR) n = 6, UST (R) n = 11; IFX (NR) n = 13, IFX (R) n = 6, Wilcoxon rank-sum test, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. E . Heatmap of correlation between immune cells infiltration and each of the following: response to ustekinumab, response to infliximab, and the occurrence of psoriasis (IFX, response to infliximab; UST, response to ustekinumab; PS, psoriasis); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. F . ROC curves of prediction models (validation group) for the likelihood of achieving an endoscopic response by intestinal mucosa proteomics; activated CD8 T cell AUC: 0.675 (95% CI: 0.333–1.000), turquoise AUC: 0.750 (95% CI: 0.500–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000). G . ROC curves of prediction models (validation group) for the likelihood of achieving an endoscopic response by body fluids proteomics; HGFAC (plasma) AUC: 0.780 (95% CI: 0.333–1.000), HGFAC (urine) AUC: 0.780 (95% CI: 0.333–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000). H . ROC curves of prediction models (validation group) for likelihood of the development of CDPS constructed using selected features by lasso regression; turquoise AUC: 0.960 (95% CI: 0.750–1.000), KRT7 AUC: 0.622 (95% CI: 0.333–1.000), HGFAC (plasma) AUC: 0.750 (95% CI: 0.500–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000).

Journal: eBioMedicine

Article Title: Significance of integrated clinical and proteomic characteristics analysis for pathogenesis and management of Crohn's disease with concomitant psoriasis

doi: 10.1016/j.ebiom.2025.105981

Figure Lengend Snippet: Prediction of CDPS and the correlation between proteomics and clinical characteristics. A . Heatmap of the correlation among expression of co-expression protein modules, expression of CDPS key proteins and clinical characteristics (IFX, response to infliximab; UST, response to ustekinumab; PS, psoriasis; NEUT, neutrophils; CRP, C-reactive protein; WBC, white blood cell; ESR, erythrocyte sedimentation rate; ALB, albumin; SES-CD, simple endoscopic score for Crohn's Disease); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. B . Heatmap of correlation between immune cell infiltration and expression of co-expression modules and CDPS key proteins; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. C . Box plot of expression of co-expression modules in response (R) and non-response (NR) group (UST, ustekinumab; IFX, infliximab); UST (NR) n = 6, UST (R) n = 11; IFX (NR) n = 13, IFX (R) n = 6, Wilcoxon rank-sum test, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. D . Box plot of level of immune cells infiltration in response (R) and non-response (NR) group (UST: ustekinumab; IFX, infliximab); UST (NR) n = 6, UST (R) n = 11; IFX (NR) n = 13, IFX (R) n = 6, Wilcoxon rank-sum test, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. E . Heatmap of correlation between immune cells infiltration and each of the following: response to ustekinumab, response to infliximab, and the occurrence of psoriasis (IFX, response to infliximab; UST, response to ustekinumab; PS, psoriasis); ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. F . ROC curves of prediction models (validation group) for the likelihood of achieving an endoscopic response by intestinal mucosa proteomics; activated CD8 T cell AUC: 0.675 (95% CI: 0.333–1.000), turquoise AUC: 0.750 (95% CI: 0.500–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000). G . ROC curves of prediction models (validation group) for the likelihood of achieving an endoscopic response by body fluids proteomics; HGFAC (plasma) AUC: 0.780 (95% CI: 0.333–1.000), HGFAC (urine) AUC: 0.780 (95% CI: 0.333–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000). H . ROC curves of prediction models (validation group) for likelihood of the development of CDPS constructed using selected features by lasso regression; turquoise AUC: 0.960 (95% CI: 0.750–1.000), KRT7 AUC: 0.622 (95% CI: 0.333–1.000), HGFAC (plasma) AUC: 0.750 (95% CI: 0.500–1.000), multi-omics model AUC: 0.830 (95% CI: 0.500–1.000).

Article Snippet: Feature selection for the faecal proteomics data was performed using the least absolute shrinkage and selection operator (LASSO) logistic regression model.

Techniques: Expressing, Sedimentation, Biomarker Discovery, Clinical Proteomics, Construct